

FOSUN 复星

为 幸 福 生 活



微信公众号
WeChat



微博号
Weibo



视频号
WeChat



抖音号
Douyin(Tik Tok)

香 港
香港中环花园道3号中国工商银行大厦808室
电话：+ 852 2509 3228
传真：+ 852 2509 9028

上 海
上海市黄浦区中山东二路600号外滩金融中心
电话：+ 86 21 2315 6666
传真：+ 86 21 6130 3288
邮编：200010

北 京
北京市朝阳区朝阳北路237号复星国际中心
电话：+86 10 5915 2299

纽 约
44th Floor, 28 Liberty St, New York, NY 10005 USA
电话：+1 646 553 5892

里斯本
Largo do Chiado 8, 1249-125 Lisbon, Portugal
电话：+ 351 213 401 500

伦 敦
Units 18 & 19, Part First Floor, The Royal Exchange, London EC3V 3LN
邮箱：londonoffice@fosun.com

HONG KONG, CHINA
Address : Room 808, ICBC Tower, 3 Garden Road, Central
Tel : +852 2509 3228
Fax : +852 2509 9028

SHANGHAI, CHINA
Address : Building S1, Bund Finance Center, No. 600, Zhongshan East 2nd Road, Huangpu District
Tel : +86 21 2315 6666
Fax : +86 21 6130 3288
Postcode : 200010

BEIJING, CHINA
Address : Fosun International Center, No. 237, Chaoyang North Road, Chaoyang District, Beijing
Tel : +86 10 5915 2299

NEW YORK, USA
Address : 28 Liberty Street, 44th Floor, New York, NY 10005, USA
Tel : +1 646 553 5892

LISBON, PORTUGAL
Address : Largo Do Chiado 8, 1249-125 Lisbon, Portugal
Tel : +351 213 401 500

LONDON, UK
Address : Units 18 & 19, Part First Floor, The Royal Exchange, London EC3V 3LN
Email : londonoffice@fosun.com



FOSUN 复星

植根中国，服务全球家庭客户
智造健康、快乐、富足的幸福生态系统

Rooted in China, Creating a Global Happiness Ecosystem
Fulfilling the Needs of Families Worldwide in Health, Happiness and Wealth

复星 2025年5月
FOSUN (May 2025)

CONTENTS 目录

02 | About Fosun 我们是谁

06 | Fosun's Strategy 我们的战略

18 | Business Overview 我们的业务

28 | Our Pursuit 我们的追求

除特别注释，本画册内数据均截至2024年12月31日
Unless otherwise specified, all figures in this brochure are as of 31 December 2024

复星，为幸福生活 FOSUN, TOWARDS A BRIGHTER LIFE

使命 MISSION


让全球家庭生活更幸福
Creating happier lives for families worldwide

愿景 VISION

植根中国，服务全球家庭客户
智造健康、快乐、富足的幸福生态系统
Rooted in China, Fosun is committed to creating a global happiness ecosystem fulfilling the needs of families worldwide in Health, Happiness, and Wealth

价值观 VALUE

修身，齐家，立业，助天下
Self-improvement, Teamwork, Performance, and Contribution to Society



创新驱动的 全球家庭消费产业集团

A GLOBAL INNOVATION-DRIVEN
CONSUMER GROUP

复星创立于1992年，经过逾30年发展，已成为一家创新驱动的全球家庭消费产业集团。秉持让全球家庭生活更幸福的使命，复星致力于服务全球家庭客户，战略聚焦健康、快乐、富足的幸福生态系统。2007年复星国际在香港联交所主板上市（股份代号：00656.HK）。

Fosun was founded in 1992. After more than 30 years of development, Fosun has become a global innovation-driven consumer group. Adhering to the mission of creating happier lives for families worldwide, Fosun is committed to creating a global happiness ecosystem fulfilling the needs of families worldwide in Health, Happiness and Wealth. In 2007, Fosun International Limited was listed on the main board of the Hong Kong Stock Exchange (stock code: 00656.HK).

我们是谁

ABOUT FOSUN

1,921.4 亿元 / 192.14 billion

2024年度总收入
Total Revenue in 2024

7,965 亿元 / 796.5 billion

总资产
Total assets

49.0 亿元 / 4.9 billion

产业运营利润¹
Industrial operation profit¹

49.3%

全球化运营，海外收入占比
Proportion of overseas revenue
from global operations

69.0 亿元 / 6.9 billion

科创投入²
建立超20家全球科创中心
Investment in technology
and innovation² with more
than 20 global technology
innovation centers established

AA

MSCI ESG评级
MSCI ESG rating

* 币种说明：本文件所含财务数据均基于2024年度业绩（截至2024年12月31日止），货币单位为人民币

¹ 产业运营利润包含集团下属产业运营附属公司及用权益法核算的联合营企业的利润贡献

² 科技与创新投入包含科研投入（费用化和资本化），但不包含数字化投入

* Currency in RMB and data for the year ended or as of 31 December 2024, unless otherwise specified

¹ It includes the profit contribution of industrial operation subsidiaries of the Group and associates and joint ventures accounted by equity method of the Group

² It includes scientific research investment (expensed and capitalized) but excludes digitalization expenses

植根中国 全球发展

ROOTED IN CHINA, DEVELOPING GLOBALLY

植根于中国，成长于全球，复星长期坚持“创新”和“全球化”两大核心增长引擎，是中国少数既积累了深厚科技与创新能力，又具备全球运营与投资能力的企业。

Rooted in China, Fosun has been developing globally and has long adhered to the two core growth drivers of "innovation" and "globalization". Fosun is one of the few Chinese companies that is equipped with global operation and investment capabilities, and has accumulated profound technology and innovation capabilities.

1992

人民币 3.8 万元创业
Fosun was founded
with a capital of RMB
38,000

1998

复星医药
A 股上市
Listing of Fosun
Pharma on the
Shanghai Stock
Exchange

2003

国药控股
Sinopharm
Group

2010

Club Med
复宏汉霖
Henlius

2007

海南矿业
Hainan Mining
复星国际港股上市
Listing of Fosun
International
(00656.HK) on the
Hong Kong Stock
Exchange

1994

复星医药
Fosun Pharma
复地
Forte

2002

豫园股份
Yuyuan

2011

BFC 外滩金融中心
The Bund Finance
Center

2013

三亚亚特兰蒂斯
Atlantis Sanya
佛山复星禅诚医院
Foshan Fosun
Chancheng Hospital
复锐医疗科技
Sisram Medical

2014

Fidelidade
Luz Saúde
洛克石油
ROC

2012

复星保德信人寿
Pramerica Fosun
Life Insurance

鼎睿再保险
Peak Re

复星星堡
Starcastle Senior
Living

2016

Gland Pharma
HAL
狼队
Wolverhampton
Wanderers FC
宝宝树
BabyTree
AHAVA

2015

Club Med 私有化
Privatization of
Club Med
Thomas Cook
Silver Cross

2018

LANVIN
Wolford
百合佳缘
Lovelink (formerly known
as Baihe Jiayuan)
松鹤楼
Songhelou
复星旅文港股上市
Listing of Fosun Tourism
Group ("FTG") on the
Hong Kong Stock Exchange

2017

复星联合健康保险
Fosun United
Health Insurance
直观复星
Intuitive Fosun
复星凯瑞
Fosun Kairos

2020

DJULA
WEI
舍得酒业
Shede Spirits

2019

FFT
复宏汉霖港股上市
Listing of
Henlius on the Hong Kong
Stock Exchange

2022

复朗集团纽交所上市
Listing of Lanvin Group
on the New York Stock
Exchange
夜郎古酒庄
Yelanggujiu

2024

汉曲优、汉斯状、
汉利康出海
Overseas launch of
HANQUYOU, HANSIZHUANG
and HANLIKANG
超级地中海启航
Launch of the ULTRAMED
Hainan project

2023

豫园灯会出海
Overseas debut of
Yuyuan Garden Lantern
Festival

2025

复星旅文私有化
Privatization of FTG



全球化

Globalization



创新

Innovation



FC2M



FES

01

我们的战略

OUR STRATEGIES


复星坚持全球化战略，持续创新打造新动能，锚定家庭消费产业主赛道持续深耕
Fosun adheres to its globalization strategy, continuously innovates to create new momentum, and remains focused on deepening its development in the household consumption industry

全球产业地图

GLOBAL BUSINESS FOOTPRINTS

复星的全球化以复星国际上市为起点，已走过18年路程，目前在全球超35个国家和地区拥有产业布局。自2022年以来，“全球组织+本地运营”的模式不断成熟，运营是未来复星全球化核心。

The globalization journey of Fosun began with the listing of Fosun International in Hong Kong. After 18 years since its listing, Fosun has established a business presence in more than 35 countries and regions around the world. Since 2022, the model of "global organization + local operations" has become more mature. Operations are at the core of Fosun's future globalization.




深度全球运营

PROFOUND GLOBAL OPERATIONS

复星的全球化，不止是全球和中国的“双向奔赴”，还延伸至海内外生态企业的内生式发展，鼓励生态企业在各自领域积极拓展本土以外的市场。

Fosun's globalization strategy means more than just "two-way engagement" between the global and Chinese markets. It extends to the endogenous development of its ecosystem enterprises both domestically and internationally, encouraging them to actively expand their businesses beyond their domestic markets.



推动产品服务出海

Promote Overseas Expansion of Products and Services

汉曲优®

HANQUYOU

自主研发的汉曲优®成为在中欧美获批的“中国籍”生物类似药，已在50多个国家和地区获批上市，实现中国、东南亚、北美、欧洲、中东及拉丁美洲等地区商业化供货，惠及逾24万名患者

The independently developed HANQUYOU became a "China-developed" biosimilar approved in China, the U.S., and the European Union. It has been approved for marketing in more than 50 countries and regions and has achieved commercial supply across China, Southeast Asia, North America, Europe, the Middle East, and Latin America, benefiting over 240,000 patients.

汉利康®、汉贝泰®

HANLIKANG and HANBEITAI

汉利康和汉贝泰分别在秘鲁、玻利维亚获批，复宏汉霖的海外获批自研产品达4个

HANLIKANG and HANBEITAI were approved for marketing in Peru and Bolivia, respectively, bringing the number of self-developed products approved overseas by Henlius to four.

松鹤楼

Songhelou

2025年4月，松鹤楼海外首店落户英国伦敦
In April 2025, Songhelou opened its first overseas restaurant in London, U.K.

汉斯状®

HANSIZHUANG

自主研发的汉斯状®是全球首个&欧盟唯一获批一线治疗广泛期小细胞肺癌的抗PD-1单抗，对外授权已覆盖美国、欧洲、东南亚、中东和北非等100多个国家和地区

The independently developed HANSIZHUANG became the world's first and the only anti-PD-1 monoclonal antibody approved for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in the European Union. It has been licensed out to more than 100 countries and regions, including the U.S., Europe, Southeast Asia, the Middle East, and North Africa.

豫园灯会

Yuyuan Garden Lantern Festival

豫园灯会2024年首次出海，吸引近20万法国当地民众；2025年再次启航，在越南河内和泰国曼谷举办海外灯会

Yuyuan Garden Lantern Festival made its overseas debut in 2024, attracting nearly 200,000 local visitors in France. In 2025, it has embarked on another overseas journey, with overseas editions taking place in Hanoi, Vietnam, and Bangkok, Thailand.

全球布局优质资产

Establish a Global Layout of Quality Assets

Fidelidade

复星葡萄牙保险保持葡萄牙市场领先地位，在葡以外的国际业务毛保费收入占比近30%、利润贡献占比超50%

Fidelidade has maintained its leading position in the local market, with its international business outside Portugal accounting for nearly 30% of gross written premiums and contributing over 50% of profits.

海南矿业

Hainan Mining

非洲马里布谷尼锂矿即将投产
Bougouni lithium mine in Mali, Africa is about to commence production.

Club Med

全球业绩再创新高，2024年新开3个度假村；2025年，美洲、欧非中东及亚太区预定量持续增长，计划新开马来西亚和中国龙坞2个度假村

Global business volume reached a new record high, with three new resorts opened in 2024. In 2025, bookings continue to grow across the Americas, EMEA, and Asia-Pacific regions, with plans to open two new resorts in Malaysia and Longwu, China.

鼎睿再保险

Peak Re

持续拓展全球市场，2024年底分出业务覆盖全球56个国家
Peak Re has continuously expanded its global market, and by the end of 2024, its ceded business reached 56 countries.

布局中东市场

Tap into the Middle East Market

复宏汉霖与沙特阿拉伯SVAX公司达成战略合作，海南矿业成功收购阿曼油田权益

Henlius entered into a strategic partnership with AL-TIRYAQ AL-KHALAWI Medical Company (SVAX) in Saudi Arabia, while Hainan Mining successfully acquired oil interests in Oman.



科创引领 创新驱动

TECHNOLOGY-LED & INNOVATION-DRIVEN

整合式创新，多维度提升产品竞争力，奠定可持续发展基础。

Integrated innovation enhances product competitiveness across multiple dimensions, laying a solid foundation for sustainable development.

69 亿元 / 6.9 billion

2024全年科创投入¹
Investment in technology
and innovation¹ in 2024

20+

全球科创中心
Global technology innovation centers

创新各领域科创中心 Innovative Technology Innovation Centers in Various Fields

- 复星医药全球研发中心（国家级）
 - 复星医药北美研发总部
 - 复星医药院士专家工作站
 - 江苏省万邦重组蛋白类药物工程中心
 - 江苏省万邦糖尿病治疗药物工程技术研究中心
 - 重庆市药友冻干制剂开发国家地方联合工程研究中心
 - 重庆医药工业研究院
 - 辽宁省奥鸿肿瘤及围手术期药物专业技术创新中心
 - 佛山市禅医肿瘤精准重点实验室
 - 复宏汉霖全球创新中心
 - 复星凯瑞研发中心
 - 直观复星总部产业基地
 - 万盛股份技术中心（国家级）
 - 翌耀科技全球研发中心
 - 四川省舍得白酒智能酿造工程技术中心
 - 天津市海鸥高精度机械手表企业重点实验室
 - 复星津美全球科创中心（CNAS认证）
 - 豫园文化饮食集团科创中心
 - 复星酒业全球科创研究院
 - 豫园珠宝设计师中心
 - 复朗面料创新中心
- Fosun Pharma Global R&D Center (national level)
 - Fosun Pharma North America R&D Headquarters
 - Fosun Pharma Academician Expert Workstation
 - Jiangsu Wanbang Recombinant Protein Drug Engineering Center
 - Jiangsu Wanbang Engineering Research Center for Diabetic Drugs
 - Chongqing Yao Pharma National-Local Joint Research Center for Lyophilized Preparations
 - Chongqing Pharmaceutical Research Institute
 - Liaoning AVANC Pharma Professional Technology Innovation Center for Tumor and Perioperative Drugs
 - Foshan Fosun Chancheng Hospital Tumor Precision Key Laboratory
 - Henlius Global Innovation Center
 - Fosun Kairos R&D Center
 - Intuitive Fosun Headquarters Industrial Base
 - Wansheng Technology Center (national level)
 - Easun Technology Global R&D Center
 - Sichuan Engineering Technology Center for Intelligent Brewing of Baiju
 - Tianjin Seagull High-Precision Mechanical Watch Enterprise Key Laboratory
 - Fosun Cosmetics Global Innovation Center (CNAS certified)
 - Yuyuan Foods & Dining Group Innovation Center
 - Fosun Wine & Spirits Global Innovation Center
 - Yuyuan Jewelry Creative House
 - Lanvin Group Fabric Innovation Center

^{*1} 科技与创新投入包含科研投入（费用化和资本化），但不包含数字化投入
¹ It includes scientific research investment (expensed and capitalized) but excludes digitalization expenses

研发创新 R&D Innovation

复星医药 Fosun Pharma

2024年，复星医药研发投入55.54亿元，主要在研创新药、生物类似药项目超80项（按适应症计算），推出PharmAID决策智能体平台助力药物研发提速增效

In 2024, Fosun Pharma invested RMB5.55 billion in R&D, with over 80 major pipeline projects on innovative drugs and biosimilars (calculated by indications); launched the PharmAID decision intelligence platform to optimize the innovative R&D process and improve efficiency.

冻干人用狂犬病疫苗（Vero细胞） Rabies Vaccine (Vero Cell) for Human Use (freeze dried)

复星医药自主研发冻干人用狂犬病疫苗（Vero细胞）在中国境内获批上市

Rabies vaccine (Vero cell) for human use (freeze dried) independently developed by Fosun Pharma was approved for launch in Chinese mainland.

数字化创新与AI应用 Digital Innovations and AI Applications

复星医药PharmAID决策智能体平台 Fosun Pharma's PharmAID Decision Intelligence Platform

自主研发的PharmAID决策智能体平台，将AI应用融入药物研发全生命周期，加速研发过程并辅助各个医药研发各个阶段的重要决策

The PharmAID decision intelligence platform, independently developed by Fosun Pharma, integrates artificial intelligence (AI) throughout the entire lifecycle of drug research and development (R&D), accelerating the R&D process and supporting critical decision-making at every stage of pharmaceutical R&D full stop.

复星葡萄牙保险AI虚拟助手MARIA Fosun Insurance Portugal's AI Virtual Assistant MARIA

复星葡萄牙保险使用AI虚拟助手MARIA，处理客户咨询、办理理赔、提供保单详情以及引导用户完成保险相关流程；复星葡萄牙保险推出基于 AI 的保险风险评估系统GAMA，提供更精准的客户服务

Fosun Insurance Portugal utilizes the AI virtual assistant MARIA to handle customer inquiries, process claims, provide policy information, and guide users through insurance-related procedures. Additionally, it has introduced GAMA, an AI-driven insurance risk assessment system designed to enhance customer service precision.

Ion支气管镜机器人 Ion Robotic Bronchoscopy

直观复星Ion支气管导航操作控制系统成功获批于中国境内上市，完成首台商业化装机

Intuitive Fosun's Ion System was approved for launch in Chinese mainland, and the first unit has been installed for commercial use.

复锐医疗科技 Sisram Medical

复锐医疗科技探索应用AI精准分析用户皮肤，提供个性化护理方案；许可引进的达希斐（注射用 A 型肉毒素）获国家药监局批准上市

Sisram Medical is exploring the use of AI for precise skin analysis and personalized skin care solutions. The licensed product Daxxify (botulinum toxin type A for injection) was approved for marketing by the National Medical Products Administration (NMPA).


复星旅文AI Lab Fosun Tourism Group's AI Lab

着力打造AI G.O（AI度假管家）为客户提供全旅程周期的个性化服务。Club Med上线GM Copilot，基于大模型技术，显著提升了运营效率

Fosun Tourism Group has developed the AI G.O (AI Gentle Organizer) to provide personalized services throughout the customer journey. Club Med has launched GM Copilot, powered by large model technology, significantly enhancing operational efficiency.

推动FC2M生态协同 创新FES管理体系

PROMOTE FC2M ECOSYSTEM SYNERGY &
INNOVATE FES MANAGEMENT SYSTEM



飞轮战略强力支撑 轻资产运营打造优质项目

LEVERAGE THE FLYWHEEL STRATEGY TO DEVELOP
HIGH-QUALITY PROJECTS WITH ASSET-LIGHT OPERATIONS

凭借30多年积累的深厚产业运营能力，以及在创新和全球化方面的优势，复星携手各方合作伙伴，布局优势产业，打造优质项目。

Leveraging its profound industrial operation capabilities accumulated over more than 30 years, along with its advantages in innovation and globalization, Fosun has joined hands with various partners to deploy advantageous industries and create high-quality projects.

复星医药 Fosun Pharma

联手深圳市引导基金等共同出资设立人民币50亿元生物医药产业基金，由复健资本管理
Fosun Pharma together with the Shenzhen Guidance Fund and other investors established a RMB5.0 billion biopharmaceutical industry fund, managed by Fosun Health Capital.

阿尔卑斯国际度假区二期 Taicang Alps Resort Phase II

由太仓市政府平台出资约人民币50亿元打造，复星旅文运营管理
With an investment of approximately RMB5 billion, the Taicang Alps Resort Phase II project is funded by the Taicang Municipal Government and managed by FTG.

重庆中国Mall Chongqing China Mall

复星旅文与重庆市政府平台合作，将以轻资产运营的模式负责重庆中国MALL项目的改造与运营管理，打造大型室内主题旅游娱乐公园
FTG with a Chongqing government platform to take on the renovation and operation of the Chongqing China Mall Project under an asset-light model, creating a large-scale indoor tourism and entertainment park.

深圳金沙湾轻资产运营 Asset-light operation in Jinsha Bay, Shenzhen

复星旅文深圳金沙湾轻资产运营签约，大湾区首家Club Med落地
FTG signed an asset-light operation agreement for the Jinsha Bay project in Shenzhen, marking the launch of the first Club Med in the Greater Bay Area.

Club Med

旗下共经营68家度假村，其中采用租赁及管理模式的度假村占比为85%
Club Med operates 68 resorts, with 85% of the resorts adopting a leasing and management model.

康养+保险 "Health care + Insurance"

康养+保险生态保单模式成功跑通，实现总保费收入128.5亿元，复星康养首次实现盈利
Fosun successfully implemented the "health care + insurance" ecosystem policy model, achieving premiums of RMB12.85 billion. Fosun Care achieved profitability for the first time.

领导团队

LEADERSHIP



郭广昌

Guo Guangchang

执行董事兼董事长
Executive Director
Chairman of the Company



汪群斌

Wang Qunbin

执行董事兼联席董事长
Executive Director
Co-Chairman of the Company



陈启宇

Chen Qiyu

执行董事兼联席首席执行官
Executive Director
Co-CEO of the Company



徐晓亮

Xu Xiaoliang

执行董事兼联席首席执行官
Executive Director
Co-CEO of the Company



龚平

Gong Ping

执行董事
执行总裁兼首席财务官
Executive Director
Executive President and
CFO of the Company



黄震

Huang Zhen

执行董事
执行总裁兼首席发展官
Executive Director
Executive President and
CGO of the Company



潘东辉

Pan Donghui

执行董事
执行总裁兼首席人力资源官
Executive Director
Executive President and
CHO of the Company

人才 复星最重要的资产

TALENT, THE MOST VALUABLE ASSET OF FOSUN

人才的厚度决定了企业未来发展的宽度和高度

A robust team of talent determines the scalability of the company's future development

良将如云

ELITE
MANAGEMENT
TEAM

160+ 全球合伙人
490+ 产业合伙人
470+ 条线合伙人
50+ 创新合伙人

160+ global partners
490+ industry partners
470+ functional line partners
50+ innovation partners

GLOCAL

GLOCAL

30+ 海外全球合伙人
来自葡萄牙、法国、
德国、英国、日本、
印度、美国等国家

30+ overseas global partners
from countries including
Portugal, France, Germany, the
United Kingdom, Japan, India,
and the United States

复星的人才观

TALENT
DEVELOPMENT
STRATEGY

以发展吸引人
以业绩考核人
以工作培养人
以事业凝聚人

Attract talent with
development,
appraise talent based
on performance,
train talent through
work, and
unite talent with career
opportunities





健康

Health




快乐

Happiness



富足

Wealth



智造

Intelligent Manufacturing

02

我们的业务

OUR BUSINESSES

复星持续深耕健康、快乐、富足、智造四大业务板块，为全球家庭客户提供高品质的产品和服务

复星医药、豫园股份、复星旅文、复星葡萄牙保险四大核心子公司总收入1346.5亿元，占集团总收入70.1%

Fosun continues to focus on its four major business segments: Health, Happiness, Wealth, and Intelligent Manufacturing, providing high-quality products and services to families worldwide.

Its four core subsidiaries – Fosun Pharma, Yuyuan, Fosun Tourism Group, and Fosun Insurance Portugal – generated a total revenue of RMB134.65 billion, accounting for 70.1% of the Group's total revenue.

健康板块

HEALTH SEGMENT

持续全球产业创新，构建医疗级、一站式、全场景的健康生态

Continue to drive global industrial innovation to create a medical-grade, one-stop, all-scenario health ecosystem

生物制药

BIOPHARMACEUTICALS

2024年自主研发及许可引进的创新药/生物类似药7个（16项适应症）获批上市；自主研发、合作开发及许可引进的8个创新药/生物类似药进入上市前审批/关键临床阶段；18个项目获批开展临床试验

In 2024, a total of 16 indications of 7 innovative drugs/biosimilars independently developed and licensed-in by Fosun were approved for launch; 8 innovative drugs and biosimilars - independently developed, co-developed through collaboration, or licensed-in - entered the pre-market approval or pivotal clinical stage; 18 innovative drugs/biosimilar projects initiated clinical trials



器械与诊断

DEVICES & DIAGNOSIS

医疗美容、呼吸健康、专业医疗设备、医学诊断

Medical aesthetics, respiratory health, professional medical devices, and medical diagnosis



健康服务

HEALTHCARE SERVICES

聚焦高品质医疗及专业服务；组合保险、健康消费、康养等，设计全流程闭环解决方案

Focusing on high-quality medical and professional services, the offerings include combined insurance, health consumption, and wellness solutions, designed to create a comprehensive closed-loop solution



快乐板块

HAPPINESS SEGMENT

围绕家庭消费和旅游文化，构建全球化、全产业的快乐生态系统

Center on family consumption and tourism to build a global, industry-wide happiness ecosystem

家庭消费

FAMILY CONSUMPTION

时尚，多元，引领家庭消费

Leverage fashion and diverse experiences to drive family consumption



文旅产业

TOURISM AND CULTURE BUSINESS

为全球家庭客户带来“度假式生活”和“生活方式度假”，匹配全球资源，打造“超级旅游目的地”，放大“旅游+”效应

Provide families worldwide with "vacation-like lifestyle" and "lifestyle-based vacation". By aligning global resources, Fosun aims to create "super tourism destinations" to amplify the "tourism+" effect



富足板块

WEALTH SEGMENT

聚焦保险、资管两大领域，打造复星富足生态产业布局

Focus on the two major fields of insurance and asset management to build the Fosun Wealth ecosystem

保险

INSURANCE

全球化产业布局，坚持创新发展与生态建设

Establish a global presence and adhere to innovative development and insurance ecosystem development

FIDELIDADE
SEGUROS DESDE 1808

复星保德信
Fosun Pramerica FOSUN

PeakRe

FOSUN HEALTH
复星联合健康保险

La Positiva
Seguros

投资类资管

INVESTMENT MANAGEMENT

产业投资+财务投资双轮驱动

全周期赋能健康、快乐、富足、智造

Leverage industrial investment + financial investment as twin drivers to empower Health, Happiness, Wealth, and Intelligent Manufacturing in every stage of life

Millennium
bcp

FOSUN CAPITAL
复星创富

复星 FOSUN
锐正 RZ CAPITAL

FOSUN WEALTH
复星财富控股

蜂巢类资管

HIVE ASSET MANAGEMENT

以城带产，以产兴城，打造全球城市蜂巢标杆

Introduce industries to cities to facilitate urban development, creating a global urban hive benchmark

FOSUN HIVE
复星蜂巢

FORTE 复地
[世界]金[地]产

BFC
THE BUNG
FRANCE CENTER
[外]国[金]融[中]心

IDÉRA
CAPITAL MANAGEMENT

PAREF

RESOLUTION
PROPERTY

28 LIBERTY

FOSUN INFRA
复星基础设施

CHSTR
Hangzhou Railway
杭绍台铁路

智造板块

INTELLIGENT MANUFACTURING SEGMENT

以战略性资源、功能性新材料和智能制造产业为主体，赋能产业高端化、智能化、绿色化转型

With strategic resources, functional new materials, and intelligent manufacturing as the core, Fosun empowers high-end, intelligent and green transformation of the industry

海南矿业
HAINAN MINING

绿色低碳资源

Green & Low-Carbon Resources

铁矿石+油气+新能源，布局战略性资源能源

Leverage iron ore, oil and gas, and new energy to establish a foothold in strategic resources and energy

铁矿石业务稳扎稳打：原矿产量实现连续三年达产，战略和长协客户订单量约占总销量75%

油气业务蓬勃发展：产量连续三年增长，获得在阿曼苏丹国4个区块的油田权益

新能源业务有序推进：氢氧化锂（一期）项目实现冶金段投料试车成功，非洲马里布谷尼锂矿即将投产

- Iron ore business steadily progressing: Raw ore production has achieved consistent output for three consecutive years, with strategic and long-term contract customers accounting for approximately 75% of total sales.
- Oil and gas business flourishing: Production capacity has increased for three consecutive years; acquired oil interests in four oil blocks in the Sultanate of Oman.
- New energy business advancing smoothly: The lithium hydroxide (Phase I) project successfully conducted trial runs for the metallurgical section, and the Bougouni lithium mine in Mali, Africa, is about to commence production.

万盛股份
WANSHENG

功能性新材料

Functional New Materials

突破先进材料核心技术，服务制造业高端化升级

Achieve breakthroughs in core technology of advanced materials to upgrade the service manufacturing industry

全球战略布局：设立墨西哥、新加坡、泰国子公司，筹建泰国生产基地

加快技术创新：RDP产品提纯工艺技术参与国际标准制定，开展产品/工艺类项目28个

拓宽产品矩阵：收购广州焯能，横向拓展产品品类，增加新的业务布局

- Global strategic expansion: established subsidiaries in Mexico, Singapore, and Thailand, and initiated the construction of a production base in Thailand.
- Accelerated technology innovation: RDP product purification technology contributed to the development of international standards, with 28 product/process-related projects launched
- Product matrix expansion: acquired Guangzhou Shine Polymer to expand product categories and explore new business areas

翌耀科技
EASUN TECHNOLOGY

工业自动化和数字化

Industrial Digitalization and Automation

智造系统的卓越引领者，助力制造业智能化转型

A leader in intelligent manufacturing systems, facilitating the intelligent transformation of the manufacturing industry

全球总部在上海正式启用，中德技术合作和全球协作全面深化

拓展新的业务区域：拓展至越南、泰国、中东、巴西等新兴市场

切入新的业务领域：切入酒业自动化、电池生产自动化、轨道交通生产自动化等新的产业应用领域

- The global headquarters in Shanghai has officially commenced operations, deepening Sino-German technological cooperation and global collaboration
- New regional markets: tapped into emerging markets including Vietnam, Thailand, the Middle East, and Brazil
- New business segments: focusing on industry applications such as automation in the liquor industry, battery production automation, and rail transit production automation

上海复星医药（集团）股份有限公司成立于1994年，是一家植根中国、创新驱动的全球化医药健康产业集团，直接运营的业务包括制药、医疗器械、医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Group Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

409.1 亿元 / 40.91 billion 112.97 亿元 / 11.30 billion

2024年度营业收入
Revenue in 2024

海外收入，覆盖美国、欧洲、非洲、印度和东南亚等海外市场
Overseas revenue, covering markets in the U.S., Europe, Africa, India, and Southeast Asia

55.5 5.55 billion 286 projects

2024年研发投入，主要在研创新药、生物类似药项目超80项（按适应症计算）

R&D investment in 2024, with over 80 major pipeline projects on innovative drugs and biosimilars (calculated by indications)

制药板块专利申请达220项
获得发明专利授权66项
The pharmaceutical segment submitted 220 patent applications and obtained 66 licensed invention patents authorization

制药
Pharmaceuticals

创新药
成熟产品及制造
疫苗
Innovative drugs
Mature products and manufacturing
Vaccines

医疗健康服务
Healthcare Services

线上医疗服务平台
线下医疗机构（含康复医疗机构）
Online medical service platform
Offline medical institutions (including rehabilitation medical institutions)

医疗器械与医学诊断
Medical Devices and Medical Diagnosis

医疗器械
医学诊断
Medical devices
Medical diagnosis

豫园股份，旗下拥有19个中华老字号、8个市级及以上非遗项目和一众领先品牌，以东方生活美学引领中华文化复兴潮流。作为中华商业第一股，豫园股份引领中华文化复兴潮流，智造植根中国的全球一流家庭快乐消费产业集团。

Yuyuan, with a portfolio of 19 China Time-Honored Brands, 8 intangible cultural heritage projects at the municipal level or higher, and a range of leading brands, leads the trend of Chinese cultural revival through oriental lifestyle aesthetics. As the first batch of Chinese commercial stocks, Yuyuan leads the trend of Chinese cultural revival and develops a world-class Happiness consumer group rooted in China.

469.2 亿元 / 46.92 billion 73%

2024年度营业收入
Revenue in 2024

消费产业收入占比
Revenue proportion from consumer industries

4,634 家 4,000 万+ / 40 million+

珠宝时尚门店数
其中智选门店突破800家
Jewelry and fashion stores, of which the number of smart selection stores exceeded 800

豫园商圈2024年客流人次
Customer traffic in Yuyuan Tourist Mart in 2024

珠宝时尚
Jewelry and Fashion

文化饮食
Cultural Food and Dining

国潮腕表
Chinese Watches

美丽健康
Beauty and Health

复合功能地产
Complex Functional Real Estate



复星旅游文化集团（简称“复星旅文”），全球领先的综合性旅游休闲度假集团之一，以“度假让生活更美好”为使命，致力于引领度假生活，智造全球领先的家庭休闲度假生态系统。

Fosun Tourism Group (also known as "FTG" and "Fosun Holiday"), is a world-leading leisure-focused integrated tourism group. Embracing the mission of "Better Holiday, Better Life", FTG endeavors to pioneer holiday lifestyle and create a world-leading family leisure and tourism ecosystem.

190.4 亿元 / 19.04 billion

2024年旅游运营营业额
Business volume from
tourism operation in 2024

Nearly / 近 70 家

酒店及度假村
Hotels and resorts

40+ 个

国家和地区
Countries and regions

24 家

滑雪度假村
Ski resorts

Club Med
地中海俱乐部

精致“一价全包”度假的全球领导者

A global leader that offers
exquisite "all-inclusive" holidays

ATLANTIS
SANYA
三亚·亚特兰蒂斯

一站式海洋主题的高端综合度假目的地

A one-stop ocean-themed integrated
high-end tourism destination

太仓阿尔卑斯国际度假区
TAICANG ALPS RESORT

一站式冰雪主题的城市度假目的地

A one-stop ice and snow-themed
urban tourism destination

丽江地中海国际度假区
LIJIANG CLUB MED RESORT

一站式旅居休闲度假目的地

A one-stop long-term stay and
leisure tourism destination

葡萄牙人寿及非人寿保险领域的市场领导者。在“经验、创新、克服及亲近”的价值观引领下，Fidelidade以「以客为本」的策略拓展业务。

Fidelidade is the market leader in Portugal, both in life and non-life segments. Guided by the values of "experience, innovation, overcoming and proximity", Fidelidade conducts its activity with a "Customer Centric Approach" strategy.

本土领先

LOCAL LEADERSHIP

- 葡萄牙市场占有率超30%
- 保持葡萄牙市场占有率第一
- Market share in Portugal exceeded 30%
- Maintained the top market share in Portugal

国际化发展

INTERNATIONAL DEVELOPMENT

- 国际业务毛保费收入占比近30%
- 国际业务利润贡献占比超50%
- 保持在秘鲁、玻利维亚等市场的领先地位
- International business gross written premiums accounted for nearly 30%
- International business profits contributed over 50%
- Maintained a leading position in markets such as Peru and Bolivia

数字创新

DIGITAL INNOVATION

- 数字化用户数超190万人，近葡萄牙总人口的20%。
- AI解决方案GAMA，全自动车险理赔率从48%提升至62%
- Total number of digital users exceeded 1.9 million, accounting for nearly 20% of Portugal's total population
- With the AI-powered solution, GAMA, the rate of fully automated processing for motor claims increased from 48% to 62%

生态协同

ECOSYSTEM SYNERGY

健康险植根于保险+医院生态

Health insurance is established within the insurance + hospital ecosystem



ESG

03



立业为善
Fosun For Good



复星艺术中心
Fosun Foundation (Shanghai)

我们的追求

OUR PURSUIT

修身，齐家，立业，助天下

Self-improvement, Teamwork, Performance,
and Contribution to Society

ESG成果显著

REMARKABLE ESG ACHIEVEMENTS

碳中和战略

CARBON NEUTRALITY STRATEGY

- 力争于2028年实现碳达峰、2050年实现碳中和
- EHS管理框架
- 气候风险应对
- Strive to peak carbon emissions by 2028 and achieve carbon neutrality by 2050
- EHS management framework
- Climate risk response

立业为善

FOSUN FOR GOOD

- 守护村医
- 助力世卫组织击退疟疾
- Rural Doctors Program
- Assist WHO in building a malaria-free world

企业治理

CORPORATE GOVERNANCE

- 持续优化/进化企业风险管理
- 完善的ESG管治架构
- 积极的双向交流沟通
- 依据GRI标准和联交所气候新规加强信息披露
- Continue to optimize and evolve corporate risk management
- Improve ESG governance structure
- Proactive two-way communication
- Strengthen information disclosure based on GRI standards and Hong Kong Stock Exchange's New Climate Requirements

AA MSCI ESG

连续四年保持AA评级

Rating maintained at AA for four consecutive years

AA- 恒生ESG / HSI ESG

2024年评级跃升AA-

Rating upgraded to AA- in 2024

前5% 标普全球同业排名
Top 5% S&P's ranking among global peers

标普全球ESG评分跻身全球同业排名前5%；入选标普中国最佳1%，并荣获“行业最佳进步企业”

Fosun International's S&P Global ESG score ranked in the top 5% among global peers; Fosun International was selected as the top 1% in S&P Global's Sustainability Yearbook 2024 (China Edition) and recognized as Industry Mover

3.7分 富时罗素ESG评级
FTSE Russell ESG score

连续多年入选富时罗素社会责任指数成分股

Consistently recognized as a constituent of the FTSE4 Good Index



复星立业为善

FOSUN FOR GOOD

复星基金会成立于2012年，秉承复星“修身、齐家、立业、助天下”的理念，与国家发展同频共振，公益行动涵盖全球应急救灾、乡村振兴、健康帮扶、青年创业、教育及文化艺术等领域，公益足迹辐射全球多个国家和地区，中国社会组织评级为“5A”。

在乡村振兴领域，乡村医生项目为农村地区培养并留住合格乡村医生，提升基层医疗卫生服务能力和可及性，助力乡村振兴和“健康中国2030”；

“青少年远见者新星奖”支持用创新公益项目践行联合国可持续发展目标的青少年，推动中国青少年公益走向国际舞台；“Protechting全球青年创新创业大赛”助力AI时代全球科创青年在商业、金融、ESG等领域融合发展；

面对全球突发的各类灾情，复星基金会发挥人道主义精神，第一时间集结多方力量，为灾区送去专业支援和温暖。

Established in 2012, the Fosun Foundation upholds Fosun's corporate values of "Self-improvement, Teamwork, Performance and Contribution to Society", aligning its efforts with national development. Its philanthropic initiatives encompass global emergency disaster relief, rural revitalization, healthcare support, youth entrepreneurship, education, and culture & arts, etc., with its impact reaching numerous countries and regions worldwide. The Fosun Foundation has been rated as a 5A China Social Organization.

Regarding rural revitalization, the Rural Doctors Program trains and retains qualified rural doctors while enhancing the capacity and accessibility of primary healthcare services, supporting both rural development and the "Healthy China 2030" initiative.

The Emerging Visionaries Award empowers youth to practice the United Nations Sustainable Development Goals (UN SDGs) through innovative public service projects, promoting Chinese youth philanthropy on the global stage. The Protechting Open Innovation Program fosters young innovators worldwide in the AI era, enabling their integration and growth in business, finance, environmental, social, and governance (ESG), and beyond.

In response to sudden global disasters, the Fosun Foundation embodies the spirit of humanitarian aid, swiftly mobilizing diverse resources to deliver professional assistance and warmth to the affected areas.



Protechting全球青年创新创业大赛 Protechting Open Innovation Program

自 2016 年启动以来，Protechting 累计已吸引来自全球 60 多个国家和地区的近 1000 个项目申请。Protechting 7.0将可持续性作为核心，重点关注保险、科技、医疗和AI为核心技术的创新解决方案，全球346份申请案例参与，四强团队于2025年诞生并受邀到中国开展系列路演交流，探寻更多合作可能。

Since its launch in 2016, the Protechting program has attracted nearly 1000 applications from over 60 countries and regions worldwide. Protechting 7.0 places sustainability at its core, focusing on innovative solutions in insurance, technology, healthcare and AI-driven fields. With 346 global project submissions, four finalists have been announced in 2025 and have been invited to participate in roadshows in China to explore collaboration opportunities.

青少年远见者新星奖 Emerging Visionaries Award

青少年远见者新星奖支持12-18岁青少年用创新公益项目践行联合国可持续发展目标，2012年引入中国后已有超过6600名中国中学生参与奖项申报，成为展示和推动中国青少年公益可持续发展的一张国际化名片。

The Emerging Visionaries Award empowers youth aged 12 to 18 to advance the UN Sustainable Development Goals (SDGs) through innovative public service projects. Since its introduction to China in 2012, the program has received applications from over 6,600 Chinese middle and high school students, establishing itself as a global platform for showcasing and fostering the sustainable development of youth philanthropy in China.



守护村医

RURAL DOCTORS PROGRAM

乡村医生是基层健康的守门人。2017年底，复星基金会在国家卫健委指导下，联合中国人口福利基金会等单位启动了“健康暖心—乡村医生项目”（简称“乡村医生项目”），围绕守护、赋能与激励，推进以“五个一”工程为抓手的全方位立体式帮扶计划，守护基层健康。

Rural doctors are the "gatekeepers" of grassroot health. In late 2017, under the guidance of the National Health Commission Poverty Relief Office, Fosun Foundation, together with China Population Welfare Foundation and other units, initiated the Health by Heart – Rural Doctors Program ("Rural Doctors Program"), which focuses on safeguarding, empowering and incentivizing rural doctors, implementing a comprehensive support plan centered around the 5 "One Action" to protect grassroots health.

422^名

驻点队员
On-site workers

78^{个县}

覆盖16个省、自治区、直辖市
78 counties covered in 16 provinces, municipalities, and autonomous regions

2.5^{万名}

守护2.5万名乡村医生
25,000 rural doctors served

300^{万户 / 3 million}

惠及300万户农村家庭
Rural families benefited

1634^{万 / 16.34 million}

惠及1634万农村人口
Rural residents benefited

二十年二十佳

20 Cases of Private Sector's Sustainable Development in China for 20 Years

乡村医生项目入选联合国全球契约组织“二十二十佳”可持续发展报告

The Rural Doctors Program was included in the "20 Cases of Private Sector's Sustainable Development in China for 20 Years" Report of the United Nations Global Compact.

全球抗疟

FIGHT AGAINST MALARIA WORLDWIDE

第二代注射用青蒿琥酯Argesun®

Second-generation artesunate for injection, Argesun®

第二代注射用青蒿琥酯（商品名：Argesun®）成为首个通过世界卫生组织预认证（WHO-PQ）的一步配制青蒿琥酯注射剂，极大提升了临床使用的便利性。

Argesun®, the second-generation artesunate for injection self-developed by Fosun Pharma has become the first artesunate injectable presented with a single solvent system that received the WHO PQ, which will further enhance the accessibility of innovative antimalarial drugs.

33^个

33个抗疟系列产品
通过WHO-PQ认证
Antimalarial drugs
prequalified by WHO

4+^{亿支 / 400 million +}

截至2024年12月31日，
复星医药向全球市场供应
了超过4亿支注射用青蒿琥
As of 31 December 2024,
Fosun Pharma had supplied a
cumulative total of over 400
million doses of artesunate
for injection globally

8000+^{万名 / 80 million +}

注射用青蒿琥酯挽救了超过
8000万名重症疟疾患者的生命
Artesunate for injection has
saved the lives of more than
80 million patients with
severe malaria

青蒿琥酯非洲捐赠项目


Artesunate Donation Project in Africa

计划三年共捐赠人民币1,000万元的青蒿素类抗疟药品
Artemisinin-based antimalarial drugs valued at
RMB10 million are set to be donated over the next
three years.

布古尼美好社区项目

Bougouni Beautiful Community Project

项目为马里当地社区捐赠价值1万美金的抗疟疾药品，
降低当地5岁以下儿童在疟疾高发季节的发病率。
Antimalarial drugs valued at USD10,000 were
donated to local communities in Mali, Africa,
aiming to reduce malaria incidence among
children under five during peak malaria seasons.



FOSUN FOUNDATION
复星艺术中心

Fosun Foundation (Shanghai) aims to promote contemporary art and is committed to binding Chinese and international art and culture, and promote public awareness, understanding and engagement in global contemporary art. Fosun Foundation (Shanghai) continues to support local Chinese artists, providing a broad display platform for outstanding Chinese contemporary art works. Fosun Foundation (Shanghai) is located in the Bund Finance Center. Fosun Foundation (Chengdu) was opened in June 2022. The Taicang Special project of Fosun Foundation (Shanghai) was established in November 2023. Fosun Foundation (Shanghai) participates in, witnesses and leads the development of contemporary art and culture. As an art consultant, Fosun Foundation (Shanghai) has long showcased its collection of Chinese art works in global landmark buildings such as 28 Liberty in New York to promote global cultural and artistic exchanges.



上海市文化和旅游局
“文明诚信，优享艺术”共建单位
上海公益基地、东华大学美育实践基地
Shanghai Municipal Administration of
Culture and Tourism's "Civilization and
Integrity, Art Appreciation"
co-construction unit, Shanghai
Public Welfare Base, Donghua
University Aesthetic Education
Practice Base

Organize diversified and comprehensive cross-brand activities to promote public awareness and public engagement in the latest contemporary art trends

